A detailed history of Rhenman & Partners Asset Management Ab transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 364,500 shares of BMRN stock, worth $24.3 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares
364,500
Previous 251,500 44.93%
Holding current value
$24.3 Million
Previous $20.7 Million 23.74%
% of portfolio
2.13%
Previous 2.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$69.02 - $93.84 $7.8 Million - $10.6 Million
113,000 Added 44.93%
364,500 $25.6 Million
Q2 2024

Aug 13, 2024

BUY
$74.43 - $92.22 $1.04 Million - $1.29 Million
14,000 Added 5.89%
251,500 $20.7 Million
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $3.77 Million - $4.46 Million
-45,000 Reduced 15.93%
237,500 $20.7 Million
Q4 2023

Feb 13, 2024

SELL
$76.22 - $98.51 $7.43 Million - $9.6 Million
-97,500 Reduced 25.66%
282,500 $27.2 Million
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $13.4 Million - $15.5 Million
155,000 Added 68.89%
380,000 $32.9 Million
Q1 2023

May 11, 2023

SELL
$87.74 - $117.27 $2.54 Million - $3.4 Million
-29,000 Reduced 11.42%
225,000 $21.9 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $1.38 Million - $1.85 Million
17,000 Added 7.17%
254,000 $26.3 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $7.97 Million - $9.4 Million
97,000 Added 69.29%
237,000 $20.5 Million
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $5.72 Million - $6.95 Million
-80,000 Reduced 36.36%
140,000 $11.6 Million
Q1 2022

May 13, 2022

SELL
$74.28 - $92.69 $3.34 Million - $4.17 Million
-45,000 Reduced 16.98%
220,000 $17 Million
Q4 2021

Feb 11, 2022

BUY
$71.72 - $91.47 $1.79 Million - $2.29 Million
25,000 Added 10.42%
265,000 $23.6 Million
Q3 2021

Nov 12, 2021

BUY
$74.77 - $85.47 $5.98 Million - $6.84 Million
80,000 Added 50.0%
240,000 $18.6 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $1.51 Million - $1.7 Million
-20,000 Reduced 11.11%
160,000 $13.4 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $24.7 Million - $29.9 Million
-330,000 Reduced 64.71%
180,000 $13.6 Million
Q4 2020

Jan 19, 2021

SELL
$72.61 - $90.2 $17 Million - $21.1 Million
-234,354 Reduced 31.48%
510,000 $44.7 Million
Q3 2020

Oct 13, 2020

BUY
$71.87 - $131.03 $39.8 Million - $72.6 Million
554,354 Added 291.77%
744,354 $56.6 Million
Q2 2020

Jul 16, 2020

BUY
$79.55 - $124.22 $410,080 - $640,354
5,155 Added 2.79%
190,000 $23.4 Million
Q1 2020

Apr 16, 2020

SELL
$71.37 - $96.85 $1.8 Million - $2.44 Million
-25,155 Reduced 11.98%
184,845 $15.6 Million
Q4 2019

Jan 17, 2020

SELL
$64.27 - $86.37 $5.17 Million - $6.95 Million
-80,491 Reduced 27.71%
210,000 $17.8 Million
Q3 2019

Oct 16, 2019

BUY
$67.4 - $85.11 $616,170 - $778,075
9,142 Added 3.25%
290,491 $19.6 Million
Q2 2019

Jul 22, 2019

BUY
$80.35 - $93.9 $4 Million - $4.68 Million
49,800 Added 21.51%
281,349 $24.1 Million
Q1 2019

Apr 11, 2019

BUY
$84.2 - $98.62 $4.63 Million - $5.42 Million
55,000 Added 31.15%
231,549 $20.6 Million
Q4 2018

Feb 05, 2019

SELL
$80.14 - $106.07 $7.08 Million - $9.37 Million
-88,300 Reduced 33.34%
176,549 $15 Million
Q3 2018

Oct 03, 2018

BUY
$93.92 - $105.72 $2.35 Million - $2.64 Million
25,000 Added 10.42%
264,849 $25.7 Million
Q2 2018

Jul 20, 2018

BUY
$76.01 - $99.03 $2.66 Million - $3.47 Million
35,000 Added 17.09%
239,849 $22.6 Million
Q1 2018

Apr 11, 2018

BUY
$77.67 - $92.63 $5.05 Million - $6.02 Million
65,000 Added 46.48%
204,849 $16.6 Million
Q4 2017

Jan 19, 2018

SELL
$80.76 - $95.13 $3.24 Million - $3.81 Million
-40,100 Reduced 22.28%
139,849 $12.5 Million
Q3 2017

Oct 13, 2017

BUY
$80.6 - $94.95 $14.5 Million - $17.1 Million
179,949
179,949 $16.7 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.